Maze Therapeutics, Inc. (MAZE) SEC Filings & Earnings Calls

Dilution risk: Issuance of pre-funded warrants dilutes existing shareholders.

“Item 3.02: issued unregistered shares, diluting existing shareholders.”

Financial distress risk: Exchange agreement may indicate cash constraints.

“Entry into Exchange Agreement with Frazier Life Sciences.”

Clinical-stage company with no approved products, relies on pipeline success.

“No license revenue in Q2 2026; net loss widening.”

Increased operating expenses may pressure cash runway if milestones are delayed.

“R&D and G&A expenses increased significantly YoY.”

Clinical-stage biopharmaceutical company with no product revenue and significant losses

“We are a clinical-stage biopharmaceutical company with a limited operating history... Since our inception, we have incurred significant operating losses and have not generated any product revenue.” · word for word

Dependence on successful development and commercialization of lead programs

“We are early in our development efforts and highly dependent on the success of our lead programs.” · word for word

Need for substantial additional capital

“We will require substantial additional capital to finance our operations and achieve our goals.” · word for word

Key finance executive departure; transition risk minimal as CFO assumes duties.

“resignation was not as a result of any disagreement”

Clinical trial risk: MZE829 and MZE782 are in Phase 2; failure in pivotal trials could impair value.

“Maze plans to initiate a pivotal trial in patients with moderate AMKD without diabetes, including those with FSGS, in the first half of 2027, subject to regulatory feedback.” · word for word

Regulatory risk: FDA feedback required for pivotal trial design; delays possible.

“Subject to regulatory feedback.” · word for word

Significant operating losses and negative cash flows

“The Company has incurred significant losses and negative cash flows from operations and expects to incur significant and increasing losses as a result of its continued research and development activities.” · word for word

Dependence on future financing

“The Company may seek to raise capital through additional term loan tranches pursuant to the Hercules Term Loan Facility, equity financings, including pursuant to the 2026 Sale Agreement, license agreements, or other sources of financing. There can be no assurance that such financing will be available or will be at terms acceptable to the Company.” · word for word

Early-stage pipeline with no approved products

“We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability. Since our inception, we have incurred significant operating losses and have not generated any product revenue.” · word for word

Reliance on collaborations for revenue

“We have entered, and may in the future enter, into strategic collaborations, transactions and licensing partnerships for research, development or commercialization of our programs, including our first therapeutic candidate MZE001, and we may not be able to realize the full value of these partnerships or our partnered programs.” · word for word

Dilution risk; use of proceeds for early-stage pipeline may not yield returns.

“use any net proceeds ... to advance research and development of the Company’s product candidates”

No product revenue and significant losses

“Since our inception, we have incurred significant operating losses and have not generated any product revenue.” · word for word

Need for additional capital

“We will require substantial additional capital to finance our operations and achieve our goals.” · word for word

Clinical trial and regulatory risk

“Our lead programs are still in early clinical development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies.” · word for word

Reliance on third-party manufacturers and CROs

“We rely on third parties to conduct current and future clinical trials, and those third parties may not perform satisfactorily or at all.” · word for word

Supply chain and geopolitical risk (BIOSECURE Act)

“We are currently parties to agreements with WuXi... If these bills become law... we may be restricted in our ability to work with WuXi and other Chinese biotechnology manufacturing companies.” · word for word

Clinical-stage company with no approved products; data still early stage.

“Phase 2 data, not yet pivotal; regulatory feedback needed.”

New debt obligation may increase financial leverage; terms not disclosed.

“Creation of a direct financial obligation; termination of prior loan.”

No product revenue, pre-commercial stage

“Since our inception, we have incurred significant operating losses and have not generated any product revenue.” · word for word

Dependence on clinical trial success

“We are early in our development efforts and highly dependent on the success of our lead programs.” · word for word

Need for additional capital

“We will require substantial additional capital to finance our operations and achieve our goals.” · word for word

No revenue from license agreements; reliance on pipeline success.

“No license revenue was recognized during the three and nine months ended September 30, 2025.” · word for word